The Breast Cancer Weight Loss (BWEL) trial (Identifier NCT02750826) is a phase III randomized trial currently underway assessing the impact of a weight loss intervention on disease recurrence in women with stage II to III HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast cancer.